🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff, VARIVAX® Pulver und Lösungsmittel zur Herstellung einer Injektionssuspension in einer Fertigspritze Varizellen-Lebendimpfstoff

    GlaxoSmithKline

    Varicella

    phase 3 small molecule active

    1 trial

  2. VAY736, -, Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe

    Novartis Pharmaceuticals

    Sjögren’s Syndrome

    phase 3 small molecule active

    1 trial

  3. VAY736, ENTECAVIR , Placebo to VAY736, TENOFOVIR DISOPROXIL , TENOFOVIR ALAFENAMIDE , -

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  4. VEC-162 20 mg

    Vanda Pharmaceuticals Netherlands B.V.

    Primary Insomnia

    phase 3 small molecule completed

    1 trial

  5. VEGF Trap-Eye (BAY86-5321)

    Regeneron UK Limited

    Diabetes Mellitus

    phase 3 mab completed

    1 trial

  6. VEGF Trap-Eye (BAY86-5321)

    Regeneron UK Limited

    Myopia, Pathological

    phase 3 mab completed

    1 trial

  7. VEGF Trap-Eye (BAY86-5321)

    Regeneron UK Limited

    Macular Edema

    phase 3 mab completed

    1 trial

  8. VEGZELMA 25 mg/mL concentrate for solution for infusion, DS-8201a

    Daiichi Sankyo

    Ovarian Cancer

    phase 3 small molecule active

    1 trial

  9. VELCADE 3.5 mg powder for solution for injection, Cyclophosphamide Tablets 50 mg, JNJ-54767414, Dexamethason 4 mg JENAPHARM®

    Janssen-Cilag International N.V.

    AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)

    phase 3 small molecule active

    1 trial

  10. VENETOCLAX, AZACITIDINE, VENETOCLAX, CYTARABINE, Ziftomenib, CYTARABINE, VENETOCLAX, Ziftomenib Placebo, Daunoblastin® 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung

    Kura Oncology

    NPM1-m and KMT2A-r Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  11. VENETOCLAX, VENETOCLAX, BENDAMUSTINE, ACALABRUTINIB, CYCLOPHOSPHAMIDE, OBINUTUZUMAB, VENETOCLAX, FLUDARABINE, RITUXIMAB

    Lacuna Pharma Pty Ltd

    Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation

    phase 3 small molecule active

    1 trial

  12. VEYVONDI 1300 IU powder and solvent for solution for injection., ADVATE 1000 IU powder and solvent for solution for injection., VEYVONDI 650 IU powder and solvent for solution for injection., ADVATE 500 IU powder and solvent for solution for injection.

    Baxalta Innovations GmbH

    Hereditary severe von Willebrand Disease in children

    phase 3 small molecule active

    1 trial

  13. VGX-3100

    INOVIO PHARMACEUTICALS, INC.

    Cervical Dysplasia

    phase 3 mab completed

    2 trials

  14. VINCRISTINE SULFATE, RITUXIMAB, RITUXIMAB, APIXABAN, Golcadomide, PREDNISONE, DOXORUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE MONOHYDRATE, Golcadomide, Golcadomide 0.2 mg capsule, Golcadomide 0.3 mg capsule, Golcadomide 0.4 mg capsule, Golcadomide, Neulasta 6 mg solution for injection, PREDNISOLONE , VINCRISTINE SULFATE

    Celgene Europe Limited

    High-risk Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  15. VIR-2218, VIR-3434, HEPCLUDEX 2 mg powder for solution for injection

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 3 small molecule active

    1 trial

  16. VIR-3434, VIR-2218

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 3 small molecule active

    1 trial

  17. VIR-7831

    Vir Biotechnology

    COVID-19

    phase 3 mab completed

    1 trial

  18. VIR-7831 (sotrovimab)

    Vir Biotechnology

    Covid19

    phase 3 mab completed

    1 trial

  19. VISIPAQUE 320 mg d’I/mL, solution injectable, LIPIODOL ULTRA FLUIDE 480 mg/ml, solution injectable, HEPARINE CHOAY 5 000 UI/1 ml, solution injectable, XYLOCAINE 5 mg/ml SANS CONSERVATEUR, solution injectable, Optiray 300 (300 mg I/mL), solution injectable en flacon

    Pari Pharma GmbH

    Knee OsteoArthritis

    phase 3 small molecule active

    1 trial

  20. VP-102

    Verrica Pharmaceuticals

    Common Warts

    phase 3 other active

    1 trial

  21. VP-102 - Cantharidin, Topical Film Forming Solution

    Verrica Pharmaceuticals

    Molluscum Contagiosum

    phase 3 other completed

    2 trials

  22. VPRIV ®,

    Takeda

    Gaucher Disease, Type 1

    phase 3 mab completed

    2 trials

  23. VRDN (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor with half-life extension), TED SC Placebo

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  24. VRDN (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor with half-life extension), TED SC Placebo

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources